BioSpace News Archive

Due to Venowave’s composition, manufacturing of the device remains uninterrupted.

Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today provides an update in respect of its final distribution to its registered shareholders (the “Final Distribution”)

The market is estimated to grow with a CAGR of 9.2% from 2019-2027.

The report highlights trends prevailing in the market, and the factors driving and hindering the market growth.

The report highlights trends prevailing in the global radiology information systems (RIS) market along with the driver and restraints pertaining to the market growth.

Findings from a study of 500 people with lupus published in Rheumatology and Therapy indicate a high level of burden with current treatments and unmet needs in managing lupus symptoms.

The American Diabetes Association®, along with the nation’s leading diabetes organizations, unveiled Let’s Talk Insulin , a campaign commemorating the 100th anniversary of the discovery of insulin.

A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin (biphasic insulin aspart 30, BIAsp 30) in adults living with type 2 diabetes, the most common form of diabetes, uncontrolled on insulin and one or two oral anti-diabetic medicines

RadNet, Inc. announced that Greg Sorensen, President of RadNet’s DeepHealth artificial intelligence division, will be hosting a call with Jefferies equity research analysts, Brian Tanquilut and Anthony Petrone, on Wednesday, June 30, 2021 at 1:00 p.m. Eastern Time.

Sensei Biotherapeutics, today announced that it is reprioritizing its pipeline programs to focus on its product candidates, including its multi-antigenic next generation ImmunoPhage candidate, now referred to as SNS-401-NG, and its monoclonal antibody SNS-VISTA (V-set Immunoglobulin Domain Suppressor of T cell Activation) candidate.